Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 6:24 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$116.17 USD
+0.71 (0.61%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $116.20 +0.03 (0.03%) 6:24 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) better-than-expected revenues and robust performance across several geographies.
Zimmer Biomet's (ZBH) Procedure Volume Grows, Costs Rise
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have struggled to maintain the recovery trend in the first half of Q1 with severe-than-expected staffing shortages and supply issues leading to procedural deferrals.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical
by Zacks Equity Research
Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.
What's in Store for West Pharmaceutical's (WST) Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances.
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.
What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.
Company News for Apr 6, 2022
by Zacks Equity Research
Companies In The News Are: ZBH, CCL, UNH, CHNG, BA.
Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage
by Zacks Equity Research
Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.
Zimmer Biomet (ZBH) New WalkAI Model to Bolster Robotics Arm
by Zacks Equity Research
WalkAI adds powerful predictive analytic capabilities to ZBEdge, Zimmer Biomet's (ZBH) suite of integrated digital and robotic technologies.
Zimmer (ZBH) Down 3.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe
by Zacks Equity Research
According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.
Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore
by Zacks Equity Research
Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.